| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.7 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.011 | 0.7 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | IU1 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |